Fitalent
VC Fund
Madrid, Spain
Fitalent (FIT Investment Talent SCR Simplified Regime SL) is a venture capital firm formed in early 2011 and registered in the special register of the National Securities Market Commission (CNMV), which invests in technology companies and proven successful products , whose main asset are people and talent .Their mission is to assistentrepreneurs to get consolidated, profitable and leading companies in the technology market segment. They want to be financial and strategic partners of the companies in which they participate.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Fitalent invests in
BiotechnologySoftwareAnalyticsHealth CarePharmaceutical
Stages Fitalent invests in
SeedFunding RoundSeries AVenture - Series UnknownSeries B
Countries Fitalent invests in
Spain
Round sizes
Seed $165k–$2.6MSeries A $329k–$4.8M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $165k–$2.6M
- Series A
- $329k–$4.8M
Investment Focus
Industry
- Biotechnology 3 (20%)
- Software 2 (13%)
- Analytics 2 (13%)
- Health Care 2 (13%)
- Pharmaceutical 2 (13%)
Stage
- Seed 5 (33%)
- Funding Round 4 (27%)
- Series A 3 (20%)
- Venture - Series Unknown 2 (13%)
- Series B 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Angel Gutierrez Borjabad
Company Building Partner
|
Company Building Partner | Total investments: 0 | Find email | |
Ángel Sánchez Díaz
Corporate Venture Partner
|
Corporate Venture Partner | Total investments: 0 | Find email | |
Francisco Lopez Luque
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Santiago Descarrega
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ability Pharmaceuticals
|
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The companydevelops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization. | $7.7M / Venture - Series Unknown / Mar 11, 2024 | |
Oncostellae
|
Oncostellae has been founded in 2013 by a group of researchers (chemists, biochemists and pharmacologists) who have a common track record in developing clinical drug candidates until phase II. Our objective is to discover and develop small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novelmodulators of validated cancer targets like e.g. nuclear receptors and kinases. The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company. | $3.2M / Venture - Series Unknown / Nov 03, 2022 | |
Citibeats
|
Citibeats is a social data analysis platform that helps decision-makers of organizations, governments, and private companies understand societal changes at scale, in real-time, guiding human-centered policy-making and investments.As an Artificial Intelligence platform with proprietary Natural Language Processing technology and Machine Learningalgorithms, it unlocks the analysis of big data about human behavior and turns it into actionable insights - regardless of the language, data source, or structure of the text. This makes it possible to get accurate assessments in real-time of people's ideas, feelings, doubts, opinions and concerns. The results can be delivered up to 90 days earlier than traditional methods - like media, polls, or surveys - which help decision-makers detect emerging risks, societal trends, and market opportunities.The Sustainability and Social Risk Monitors launched in 2022 are the first tools to uncover trends from millions of voices in real time, enabling clients to detect and contextualize social changes. The new subscription-based model has been conceived to help organizations around the globe rapidly and easily understand citizens’ questions, needs, and concerns around topics like climate change, biodiversity, sustainable cities, migration, citizen security, employment and entrepreneurship, and more. The new Phoenix product, recently launched, offers our clients to seach for any topics they might need to know to help their company grow and scale within the ethical parameters of Citibeats' technology. Phoenix delivers extremely targeted, high-frequency surveys about any topic relevant to our clients.In only 4 years we have built and scaled proprietary technology based on NLP & ML algorithms that unlock the augmented analysis of unstructured data about human behavior. It’s through this technology that we deliver the best social data platform on the market in a massively scalable way. Citibeats has been recognized internationally with prestigious awards such as: - The United Nations World Summit Awards; - The COGx for the best Artificial Intelligence for public services. - The NTT Open Innovation contest (that gave us the opportunity to work and develop a project with NTT Data) - Top 100 AI IRCAI - World Economic Forum Technology PioneerIn 2021, Citibeats was one of the first four tech companies to have implemented the fAIr LAC self-assessment tool. | $2.4M / Seed / Jul 16, 2021 | |
Boxmotions
|
Home delivery of bulky items (furniture, home appliances, large sports equipment, etc.) is a large, growing, segregated and underserved market. Retail and e-commerce are in need of a solution that delivers quality and end customer experience standards comparable to the most innovative regular parcel delivery solutions.Boxmotions' owntechnology stack and operational processes have been meticulously curated with an end-customer-centric approach, generating capabilities unseen in the bulky items logistics industry before: scheduled time slot deliveries controlled by the end customer, delivery times x5 faster than industry average, tailored technology-guided interactions, assembly/dissassembly services, and more. We connect demand's orders with a curated pool of existing, segregated supply while guiding the whole value chain through our technology and generating incremental operational efficiency. Such model entices supply and, at the same time, provides retail and e-commerce with a capability to boost end customer experience with only competitive logistics costs.The basis of our technology stack and supply curation comes originally from an initial business line: an on-demand-storage solution for personal logistics. In our journey towards a larger market, we have always maintained our vision of making urban life easier, and more sustainable. | $2.6M / Seed / Dec 01, 2019 | |
Playstark
|
Playstark is a videogames company focused on eSports. | $878K / Series A / Jan 25, 2018 | |
SATLANTIS
|
SATLANTIS designs and manufactures high performance Earth observation payloads for small satellites.SATLANTIS is a company based in Spain and Florida (USA) that aims to connect the three vertices of the “triangle of knowledge” –universities, industries, and government agencies– to work together towards a common goal: to become a global leader inthe use of constellation of microsatellites for scientific and commercial applications.SATLANTIS' premier product is iSIM, an “Integrated Standard Imager for Earth Observation Microsatellites”. An optical imaging product family for micro satellites (20-75 kg) that will provide an unparalleled performance and and flexibility for a fraction of the cost of today's Earth Observation instruments. The company is also closing alliances with partners in the US and Europe to develop the infrastructure for manufacture, integration, launch, and operations of standardized microsatellites. | Jan 01, 2017 | |
|
Oncostellae
|
Oncostellae has been founded in 2013 by a group of researchers (chemists, biochemists and pharmacologists) who have a common track record in developing clinical drug candidates until phase II. Our objective is to discover and develop small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novelmodulators of validated cancer targets like e.g. nuclear receptors and kinases. The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company. | Jan 01, 2017 | |
Shoppermotion
|
Shoppermotion has developed a proprietary indoor mapping technology that allows retailers to understand consumer behaviour more effectively.Massive behavior analysis turned into actionable insights: -Measure customer flow in-store based on thousands of shoppers -Correlation between different areas in the store -Find blind spots andalign staffing schedules to traffic -Accurately track the complete journey of every visitor passively and anonymously -Transform collected data into actionable analytics to maximize operational and strategic decisions | Jan 01, 2016 | |
Irisbond
|
Irisbond creates a new way for humans to communicate through precision eye-tracking technology. Irisbond’s advanced software algorithms interpret your eye gaze in order to provide natural, intuitive and hands-free access to information and control over a screen. Developed for use in mobile devices, automotive, smart homes, robotics, scientific,healthcare and manufacturing, eye tracking technology lets you learn, play, work and communicate with your eyes. A pioneer in the assistive technology market, Irisbond’s eye tracking solutions are based on years of R&D in cooperation with Vicomtech, a leader in the field of artificial vision. For more information about the power of the eyes, go to www.irisbond.com/en | $329K / Series A / Feb 10, 2015 | |
LPS Ingeniería
|
LPS is focus on network engineering services, legalization services, energy and environment, PMO & outsourcing, business coordination. | Jan 01, 2015 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
FAQ
What does Fitalent invest in?
Fitalent invests primarily in Biotechnology, Software and Analytics startups, most often at Seed and Funding Round stage. Most of the 15 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fitalent's check size?
Fitalent typically joins rounds of $165k–$2.6M at Seed and $329k–$4.8M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fitalent participates in.
How do I contact Fitalent?
Public channels for Fitalent include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fitalent?
The team at Fitalent includes Angel Gutierrez Borjabad (Company Building Partner), Ángel Sánchez Díaz (Corporate Venture Partner) and Francisco Lopez Luque (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
